In a report published Thursday, Morgan Stanley (MS) analysts initiated coverage on Intercept Pharmaceuticals, Inc. (ICPT) with an ‘Underweight‘ rating and $165 price target. On valuation measures, Intercept Pharmaceuticals Inc. shares currently have a PEG ratio and price/book of -3.31 and 6.88, respectively. Price/sales for the same period is 2,021 while EPS is ($7.11). Currently […] View the full post at: Notable Downgrades: Intercept Pharma (ICPT), Alibaba Group (BABA), Keurig Green Mountain (GMCR), SunEdison (SUNE) Related posts: Green Mountain Coffee Roasters: When Great is Not Enough One Green Shoot and Lots of Weeds in Japan’s Economic Data Japan’s Shionogi To Acquire Sciele Pharma (SCRX) for $1.42 Billion